title: The correlation between the subsets of tumor infiltrating memory T cells and the expression of indoleamine 2,3-dioxygenase in gastric cancer.
abstract: BACKGROUND
  Although many researchers have concentrated on the mechanism of T cell anergy resulting from over-expression of Indoleamine 2,3-dioxygenase (IDO), it remains unclear what alterations will developed in memory T cells (Tm) under over-expression of IDO.
  
  
  METHODS
  Immunohistochemical staining for IDO expression in gastric cancer tissues (n=50) was carried out. Tumor-infiltrating memory Tm cells were counted by flow cytometry. The association between IDO expression and the subsets of tumor infiltrating Tm are discussed.
  
  
  RESULTS
  The higher IDO expressions were significantly associated with deeper invasion (P=0.016) and higher frequencies (P=0.038) of lymph node metastasis. The lower tumor-infiltrating CD4+Tm were significantly associated with the advanced clinical stage (P=0.026) and lymph node metastasis (P=0.016). The lower percentages of CD8+Tm were significantly related to undifferentiated histological type (P=0.042) and lymph node metastasis (P=0.037). However, the lower percentage of CD8+Tem was significantly correlated to differentiated histological type (P=0.017), lower frequencies of lymph node metastasis (P=0.014), and earlier clinical stage (P=0.008). The higher IDO expression patients had significantly lower percentages of CD4+Tm (P=0.012) and CD8+Tm (P=0.033). Nevertheless, it was confirmed that the higher level of IDO expression correlated with higher percentages of CD8+Tm cells in univariate and multivariate analysis (P=0.011).
  
  
  CONCLUSIONS
  IDO over-expression and Tm in tumor microenvironments were correlated with the disease stage and histological type of gastric cancer. Higher IDO expression was related to the lower percentage of CD4+Tm and CD8+Tm, whereas the higher level of IDO expression related with a higher percentage of CD8+Tem.
authors: Department of Gastric Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
authors: Rupeng
authors: R
authors: Zhang
authors: Hui
authors: H
authors: Liu
authors: Fangxuan
authors: F
authors: Li
authors: Hui
authors: H
authors: Li
authors: Jinpu
authors: J
authors: Yu
authors: Xiubao
authors: X
authors: Ren
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology / Q000276:immunology / Q000473:pathology*; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000096:biosynthesis*; D016015:Logistic Models; D008207:Lymphatic Metastasis / Q000473:pathology; D016246:Lymphocytes, Tumor-Infiltrating / Q000201:enzymology / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D013270:Stomach / Q000276:immunology / Q000473:pathology; D013274:Stomach Neoplasms / Q000201:enzymology / Q000276:immunology / Q000473:pathology*
chemical_list: D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase
references: Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6
references: 15980149
references: Expert Rev Vaccines. 2009 Nov;8(11):1535-9
references: 19863245
references: Trends Immunol. 2001 Aug;22(8):409-11
references: 11473821
references: Nature. 1999 Oct 14;401(6754):708-12
references: 10537110
references: Gynecol Oncol. 2010 Jun;117(3):423-8
references: 20350764
references: APMIS. 2009 May;117(5-6):356-81
references: 19400862
references: J Immunol. 2006 Jun 1;176(11):6752-61
references: 16709834
references: J Immunol. 2007 Apr 1;178(7):4260-6
references: 17371982
references: Int J Immunopathol Pharmacol. 2006 Apr-Jun;19(2):317-30
references: 16831299
references: Clin Dev Immunol. 2011;2011:469135
references: 22110525
references: Cancer Biol Ther. 2009 Jul;8(14):1402-8
references: 19597340
references: Clin Cancer Res. 2008 Apr 15;14(8):2310-7
references: 18413819
references: J Biol Chem. 2004 May 28;279(22):22820-32
references: 15010461
references: Mol Ther. 2012 Apr;20(4):860-9
references: 22186790
references: Mol Med Rep. 2011 Jan-Feb;4(1):169-73
references: 21461581
references: Br J Cancer. 2011 Oct 11;105(8):1191-6
references: 21934683
references: Br J Cancer. 2008 Nov 18;99(10):1704-11
references: 18941457
references: Nature. 2009 Jul 2;460(7251):108-12
references: 19543266
references: J Clin Oncol. 2011 Feb 20;29(6):601-3
references: 21245434
references: Int J Biol Sci. 2011;7(5):651-8
references: 21647333
references: Semin Immunol. 2007 Jun;19(3):162-72
references: 17383196
references: Curr Opin Organ Transplant. 2008 Feb;13(1):31-5
references: 18660704
references: BMC Cancer. 2010 Nov 05;10:608
references: 21054833
references: Clin Cancer Res. 2006 Feb 15;12(4):1144-51
references: 16489067
references: N Engl J Med. 2005 Dec 22;353(25):2654-66
references: 16371631
references: Neoplasia. 2005 Apr;7(4):390-6
references: 15967116
references: J Exp Med. 1999 May 3;189(9):1363-72
references: 10224276
references: J Clin Invest. 2001 Sep;108(6):871-8
references: 11560956
references: Cancer Sci. 2011 Dec;102(12):2214-20
references: 21899659
references: Nat Rev Immunol. 2004 Oct;4(10):762-74
references: 15459668
references: J Pathol. 2010 Dec;222(4):350-66
references: 20927778
references: Biochem Biophys Res Commun. 2005 Dec 9;338(1):12-9
references: 16176799
references: Semin Cancer Biol. 2006 Feb;16(1):3-15
references: 16153857
references: Behav Brain Res. 2012 Mar 1;228(1):151-8
references: 22178316
references: J Biol Chem. 2001 Mar 30;276(13):9583-6
references: 11266435
references: Nat Immunol. 2003 Mar;4(3):225-34
references: 12563257